Monitoring Blood Glucose Curves in Diabetic Dogs and Cats

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• Serial blood glucose curve measurement is the principal method for evaluating insulin efficacy in diabetic dogs and cats, requiring sampling every 2 hours for 12 to 24 hours to capture the nadir, duration of effect, and fasting trend.
• The nadir, or lowest glucose value on the curve, is critical for determining safety margins and varies by species and insulin type, with target ranges generally between 100-200 mg/dL for dogs and 80-150 mg/dL for cats.
• The Somogyi effect, a paradoxical hyperglycemia following hypoglycemia, must be distinguished from simple underdosing; it requires dose reduction, whereas waning insulin effect necessitates a dose increase or more frequent dosing.
• Insulin dose adjustments should be made incrementally (10-25% for dogs, smaller for cats) and one variable at a time (dose or timing) to avoid obscuring the effect of changes.
• Species-specific considerations are paramount, with cats prone to stress hyperglycemia in hospital necessitating home curves or continuous glucose monitoring, while dogs are more affected by meal timing relative to insulin.
• Continuous glucose monitoring (CGM) offers a more complete picture of glycemic variation than intermittent curves, detecting nocturnal hypoglycemia and providing valuable data for complex cases, though cost and owner acceptance remain considerations.

Serial blood glucose curve measurement is the principal method for evaluating insulin efficacy in diabetic dogs and cats. This article addresses the practicing veterinarian who manages diabetic patients on maintenance insulin therapy and needs a structured approach to curve generation, interpretation, and dose adjustment. The focus is procedural: how to perform curves, what patterns indicate adequate or inadequate glycemic control, and how to translate curve data into rational insulin dose modifications. Initial diagnostic workup for diabetes mellitus and management of diabetic ketoacidosis are outside the scope of this discussion.

The clinical question this article answers is direct: given a patient on insulin, is the current dose safe, effective, and appropriately timed, and if not, what change should be made? Blood glucose curves provide the data needed to answer that question, but only when generated with attention to technique and interpreted with an understanding of insulin pharmacodynamics in each species. The sections that follow build from physiologic principles through practical curve execution to interpretation frameworks and dose adjustment algorithms.

At a Glance

Physiologic Basis of Glucose Curve Monitoring

Insulin Pharmacodynamics in Dogs and Cats

Exogenous insulin preparations differ in onset, peak, and duration of action, and these properties vary between dogs and cats. Neutral protamine Hagedorn (NPH) insulin typically peaks 4 to 8 hours after subcutaneous injection in dogs with a duration of 12 to 18 hours. Lente and ultralente insulins show intermediate profiles. Porcine lente insulin has been a traditional choice in dogs, while protamine zinc insulin (PZI) and glargine are more commonly used in cats due to their longer, flatter profiles that better match feline insulin requirements. Insulin glargine, a basal analogue, has a relatively peakless profile in cats that can last 12 to 24 hours, making it suitable for twice-daily dosing in most feline patients.

The pharmacodynamic profile in an individual patient is influenced by injection site, subcutaneous fat thickness, body condition, concurrent disease, and the presence of anti-insulin antibodies. These variables mean that published duration estimates serve only as starting expectations. The blood glucose curve is the practical tool that reveals the actual profile in the patient being treated.

Hepatic Glucose Handling and Counterregulation

The liver is the primary regulator of fasting glucose production through glycogenolysis and gluconeogenesis, both suppressed by insulin and stimulated by glucagon. When exogenous insulin drives glucose below the renal threshold, counterregulatory hormones including glucagon, epinephrine, cortisol, and growth hormone are released. This response can produce rebound hyperglycemia, the Somogyi effect, which complicates curve interpretation. A curve showing hypoglycemia followed by marked hyperglycemia can be mistaken for simple underdosing, and increasing the insulin dose in that setting worsens the problem.

The renal threshold for glucose in dogs is approximately 180 to 220 mg/dL and in cats approximately 200 to 290 mg/dL, though individual variation exists. Glucosuria occurs only above these thresholds, which is why urine glucose testing is insensitive for detecting hypoglycemia and provides no information about nadir values. Blood glucose measurement is required for accurate curve assessment.

Curve Generation Protocols

In-Hospital Versus Home Curves

In-hospital curves are the standard approach in most practices. The patient is admitted in the morning, a baseline glucose is measured, insulin is administered at the usual time with food, and glucose is measured every 2 hours for 8 to 12 hours. A 12-hour curve captures the full dosing interval for twice-daily insulin regimens. A 24-hour curve may be needed for once-daily regimens or when duration of effect is uncertain.

Hospitalization introduces stress that can elevate glucose, particularly in cats. Feline patients may show stress hyperglycemia that obscures the true curve, and some cats eat poorly in hospital, altering glucose dynamics. For cats that are difficult to sample or markedly stressed, a home curve performed by the owner using a portable glucose meter may provide more representative data. The veterinarian must train the owner in meter use, ear or paw pad sampling, and curve recording. Home curves carry the risk of owner error and incomplete data, but they avoid the artifactual elevations of hospitalization.

Sampling Frequency and Technique

Blood glucose should be measured immediately before insulin administration and then every 2 hours for the duration of the curve. Sampling every 1 hour provides finer resolution around the expected nadir but increases patient stress and cost. Sampling every 4 hours may miss the nadir entirely, especially with rapid-acting insulins. The pre-injection sample establishes the fasting baseline, and the final sample at 12 hours indicates whether glucose is rising, falling, or stable at the end of the dosing interval.

Samples can be obtained by venipuncture or by capillary sampling from the ear margin or lip using a lancet. Portable glucose meters calibrated for veterinary use are acceptable for monitoring trends, though they may deviate from laboratory reference methods at extreme values. The same meter should be used throughout a curve to minimize inter-device variation. Quality assurance principles for veterinary clinical pathology, including appropriate use of point-of-care devices, are outlined in the American Society for Veterinary Clinical Pathology quality assurance guidelines.

Continuous Glucose Monitoring

Continuous glucose monitoring (CGM) systems use subcutaneous sensors to record interstitial glucose every few minutes for up to 14 days. These devices provide a far more complete picture of glycemic variation than intermittent curves and can detect nocturnal hypoglycemia that episodic sampling misses. CGM is increasingly used in veterinary practice, though sensor accuracy in dogs and cats requires validation against blood glucose measurements. The MSD Veterinary Manual discusses CGM applications in diabetic patient monitoring. Cost and owner acceptance remain limiting factors, but CGM is particularly valuable for patients with suspected Somogyi effect, erratic curves, or poor response to dose adjustments.

Curve Interpretation Frameworks

Identifying the Nadir and Duration of Effect

The nadir is the lowest glucose value on the curve, and its timing relative to insulin injection defines the peak of insulin action. A nadir that occurs earlier than expected suggests the insulin is peaking faster than predicted, which may indicate a need for a different insulin type or a change in injection timing relative to meals. A nadir that occurs late suggests delayed absorption, possibly from injection into fibrous tissue or from an insulin formulation with a longer profile than intended.

Duration of effect is determined by the time from injection until glucose returns to the pre-injection baseline or to a value above the renal threshold. If glucose rises above baseline before the next scheduled dose, the insulin duration is shorter than the dosing interval, and the patient will experience periods of hyperglycemia each day. This pattern supports increasing dosing frequency or switching to a longer-acting preparation.

Target Glucose Ranges

Target ranges vary by species and by the clinical context. For dogs, a nadir between 100 and 200 mg/dL is generally considered acceptable, with clinical signs of polyuria and polydipsia resolving when glucose stays below the renal threshold for most of the day. For cats, targets are often lower, with a nadir between 80 and 150 mg/dL, because feline diabetes is more labile and many cats can achieve diabetic remission with tight control. These targets are clinical guidelines instead of absolute values, and the MSD Veterinary Manual provides species-specific recommendations for glycemic targets in diabetic dogs and cats.

The glucose curve must be interpreted in the context of clinical signs. A curve with acceptable glucose values but persistent polyuria, polydipsia, or weight loss indicates that the curve may not reflect the patient's typical day, or that another disease process is contributing to the clinical signs. Conversely, a curve with glucose values above target but no clinical signs may justify a conservative approach to dose adjustment, particularly in cats where over-treatment carries a high risk of hypoglycemia.

Common Curve Patterns and Their Meanings

Flat Curve with Persistent Hyperglycemia

A curve where all values remain above 250 mg/dL with little variation suggests insulin underdosing, insulin resistance, or poor insulin absorption. If the curve is truly flat, the insulin may have little or no effect, and the differential diagnosis includes inactive insulin, improper storage, incorrect injection technique, or severe insulin resistance from concurrent disease. Conditions that cause insulin resistance include hyperadrenocorticism, acromegaly, infection, and obesity. A flat curve with no response to a dose increase warrants investigation for these comorbidities.

Curve with Adequate Nadir but Short Duration

When the nadir is within target but glucose rises above the renal threshold well before the next dose, the insulin effect is too short. This pattern is common with NPH insulin in dogs that require twice-daily dosing but receive the drug once daily. The solution is to split the dose into two daily injections, not to increase the total dose, since increasing the dose of a short-duration insulin prolongs the nadir and increases hypoglycemia risk without meaningfully extending duration.

Somogyi Effect

The Somogyi effect is characterized by hypoglycemia followed by rebound hyperglycemia, often to values above 300 mg/dL. The rebound occurs 4 to 8 hours after the hypoglycemic episode and can persist for 12 to 24 hours. A curve that shows a low nadir followed by rising glucose may represent either the Somogyi effect or the natural waning of insulin effect. The distinction matters because the treatment is opposite: the Somogyi effect requires a dose reduction, while waning effect requires a dose increase or more frequent dosing. A 24-hour curve or CGM may be needed to document the sequence of hypoglycemia followed by hyperglycemia.

Insulin Adjustment Algorithms

Insulin dose changes should follow a structured sequence: interpret the curve, identify the dominant problem, adjust one variable at a time, and re-evaluate within a defined interval. The two adjustable variables are dose and timing. Changing both simultaneously obscures which variable produced the observed effect.

For dogs receiving twice-daily insulin, the standard starting adjustment is a 10% to 25% increment or decrement per injection, never a doubling or halving of the total daily dose. Cats are more insulin-sensitive and often require smaller relative changes, particularly when transitioning from glargine or detemir to a different preparation. When the nadir is below the target range but the dog is asymptomatic, reduce the dose by 10% to 15% and repeat the curve in 5 to 7 days. When the nadir is frankly hypoglycemic, below approximately 3.3 mmol/L (60 mg/dL), reduce the dose immediately by 25% to 50% and instruct the owner to observe for weakness, lethargy, or ataxia. The MSD Veterinary Manual provides species-specific guidance on insulin types and expected duration of action that should be consulted before changing preparations.

Duration problems are managed differently. A curve showing adequate nadir but duration of effect under 10 hours in a twice-daily dog indicates the interval between injections exceeds insulin action. Options include increasing the dose by 10% to 20% to extend duration, switching to a longer-acting preparation, or moving the injection interval closer together, for example from 12 hours to 10 hours. Increasing the dose to extend duration risks lowering the nadir excessively. The safer sequence is to first confirm the nadir is not already at the lower end of target, then increase dose modestly, then re-curve.

Decision Points That Change the Plan

The first decision point is whether to adjust at all. A curve with a nadir in target range, glucose values between 5.5 and 11 mmol/L (100 to 200 mg/dL) for most of the day, and no clinical signs of hypoglycemia does not require dose change. Many clinicians adjust on the basis of owner-reported polydipsia or polyuria alone, but these signs lag behind glycaemic control by several days. Curve data should override owner impression when the two conflict.

The second decision point is the direction of change. Persistent hyperglycemia with a flat curve, no identifiable nadir, and glucose values above 16.5 mmol/L (300 mg/dL) throughout suggests underdosing, poor insulin absorption, or insulin resistance. Before increasing the dose, verify injection technique, insulin storage, and product potency. A dose increase in the face of poor absorption produces no effect and delays correct management.

The third decision point is the rate of change. Rapid reductions in glucose, even if the nadir remains above the hypoglycemic threshold, indicate the dose is close to the therapeutic ceiling. A drop of more than 8.3 mmol/L (150 mg/dL) from peak to nadir warrants a smaller increment on the next adjustment, or no change if clinical signs are controlled.

The fourth decision point is species. Cats frequently show a phenomenon of transient diabetic remission, where exogenous insulin requirements fall to zero after several weeks of glycaemic control. A curve in a cat with a nadir below 4.4 mmol/L (80 mg/dL) and normal fasting glucose should prompt a dose reduction of 25% to 50% or temporary cessation with close monitoring. Dogs rarely remit and require lifelong therapy in most cases.

Re-Evaluation Intervals and Curve Frequency

The interval between curve assessments depends on the stability of the patient and the magnitude of the last dose change. After a dose adjustment of 10% to 25%, repeat the curve in 5 to 7 days. After a large reduction for hypoglycemia, repeat in 3 to 5 days. Stable patients on a fixed dose for several weeks can be re-curved every 3 to 4 months, with interim assessment based on owner-reported water consumption, body weight, and urine glucose dipsticks if used.

Intercurrent illness changes the schedule. Anorexia, vomiting, or infection can precipitate diabetic ketoacidosis and requires immediate attention, not a scheduled curve. The American Veterinary Medical Association practice resources emphasize that professional judgment overrides fixed protocols when patient status changes acutely.

Documentation and Curve Reporting

A glucose curve is only useful if recorded in a format that supports pattern recognition. Record the following for each time point: clock time, blood glucose concentration, insulin dose and injection time, food intake and timing, and any observed clinical signs. The nadir, peak, and duration of effect should be identified on the curve before the clinician writes an interpretation.

A standardized curve form reduces omission errors. The form should include a grid for glucose values by time, a section for insulin and feeding times, and a comments column for activity, stress, or illness. Many practices use electronic medical record templates that generate a graphic display of the curve. The graphic display is superior to a table for identifying the nadir and the slope of glucose decline.

Document the interpretation explicitly. Write the nadir value, the time of nadir, the duration of effect, and the dominant pattern, for example "adequate nadir, short duration" or "flat curve, persistent hyperglycemia." Then record the decision and the rationale. This documentation supports continuity when a different clinician sees the patient at the next visit.

Equipment and Consumable Choices

Portable blood glucose meters validated for veterinary use are preferred over human meters, which may under-read or over-read canine and feline blood glucose. The American Society for Veterinary Clinical Pathology guidelines address method validation and quality assurance for point-of-care testing, and these principles apply to glucose meters used in practice. Confirm the meter's calibration against a laboratory reference method at least annually.

Sample site affects accuracy. Ear margin and lip capillary samples in dogs, and ear margin and paw pad samples in cats, produce values close to venous glucose when the meter is calibrated for capillary blood. Lip samples in cats are painful and poorly tolerated. Jugular or cephalic venous samples are appropriate for in-hospital curves but require restraint that may elevate glucose through stress, particularly in cats.

Test strips must be stored according to manufacturer instructions. Exposure to heat, humidity, or air degrades strip enzymes and produces falsely low or high readings. Check the expiry date before each curve. A meter that gives implausible values, for example a reading below 1.1 mmol/L (20 mg/dL) in a walking patient, should be verified against a second meter or laboratory sample before acting on the result.

Species-Specific Curve Considerations

Feline curves require interpretation in the context of stress hyperglycemia. A single elevated reading in a fractious cat may exceed 16.5 mmol/L (300 mg/dL) without reflecting true glycaemic control. The MSD Veterinary Manual notes that cats in hospital often show higher glucose values than at home, and this discrepancy can mislead dose adjustments. Home curves, or curves performed after the cat has acclimated to the hospital environment for several hours, are more reliable in this species.

Canine curves are less affected by stress but more affected by the timing of meals relative to insulin. Dogs fed immediately after injection show a postprandial glucose rise that can obscure the insulin effect. Standardize the feeding interval, typically feeding within 30 minutes of injection, and record the actual interval on the curve form.

The table above summarizes the adjustment algorithm. The thresholds are starting points, not fixed rules. Individual patients may require titration outside these ranges based on clinical response and owner-reported signs.

Recognized Complications and Early Detection

The principal failure modes in glucose curve monitoring are iatrogenic hypoglycemia, the Somogyi effect, and persistent hyperglycemia from underdosing. Each has a distinct temporal signature on the curve.

Iatrogenic hypoglycemia is the most dangerous. It appears as a nadir below 3.3 mmol/L (60 mg/dL) in dogs or below 3.9 mmol/L (70 mg/dL) in cats, often with a subsequent rebound above the starting glucose. Early detection depends on curve timing that brackets the expected peak insulin effect. A curve that begins after the nadir has passed will miss the hypoglycemic event entirely. Owners should be instructed to observe for lethargy, ataxia, hunger, or behavioral change in the hours after insulin, and any such sign warrants an immediate glucose measurement even if the scheduled curve is incomplete.

The Somogyi effect is the counterregulatory response to hypoglycemia, producing hyperglycemia that can persist for 12 to 24 hours. It is detected only by capturing the nadir. A curve showing a low nadir followed by rising glucose values, or a curve with paradoxically worsening hyperglycemia after a dose increase, should raise suspicion. The discriminating check is to repeat the curve with sampling every 1 to 2 hours across the full insulin duration, also at the times of expected peak effect.

Persistent hyperglycemia without a detectable nadir suggests underdosing, poor insulin absorption, or insulin resistance. Early detection requires distinguishing a flat curve from a curve where the nadir was missed. A flat curve with all values within a narrow range across 12 hours supports true underdosing or resistance. A curve with falling values at the final sampling point suggests the nadir occurred after the curve ended.

Common Errors and Corrective Actions

Less experienced clinicians frequently make several predictable errors. The most common is sampling too infrequently. A curve with readings every 4 hours can miss a nadir that lasts only 60 to 90 minutes. Corrective action is to sample every 1 to 2 hours, with more frequent sampling around the expected peak insulin effect.

A second error is interpreting a single glucose measurement as representative of the entire curve. A single reading cannot distinguish the Somogyi effect from simple underdosing, and it cannot establish duration of insulin effect. Corrective action is to insist on a full curve before any dose adjustment, except when hypoglycemia is suspected or confirmed.

A third error is adjusting insulin dose based on the fasting glucose alone. The fasting value reflects the end of the previous insulin duration and the hepatic glucose output, not the adequacy of the current dose. Corrective action is to base decisions on the nadir and the duration of effect, using the fasting value only as a secondary reference.

A fourth error is failing to account for the stress response in cats. A hospitalized cat may show marked hyperglycemia that does not reflect home glycaemic control. Corrective action is to prefer home curves or continuous glucose monitoring in cats, or to interpret in-hospital curves with caution when the cat is visibly stressed.

Limitations of the Evidence and Areas of Expert Disagreement

The evidence base for specific glucose targets and curve interpretation protocols in diabetic dogs and cats is largely extrapolated from human medicine and from experimental models. The American Society for Veterinary Clinical Pathology quality assurance guidelines address laboratory standards for glucose measurement but do not establish species-specific therapeutic targets. The MSD Veterinary Manual provides clinical guidance that reflects expert consensus instead of controlled trials.

Expert opinion differs on several points. The optimal nadir target remains contested, with some authorities accepting values as low as 4.4 mmol/L (80 mg/dL) in dogs and others recommending a higher floor to reduce hypoglycemia risk. The frequency of curve monitoring is also debated, with recommendations ranging from every 1 to 2 weeks during stabilization to every 3 to 4 months in stable patients. The role of fructosamine as a curve substitute is similarly contested, with some experts using it as a primary monitoring tool and others reserving it for cases where curves are impractical.

There is genuine uncertainty about the interpretation of curves in cats with diabetic remission. A cat entering remission may show declining insulin requirements that are not predicted by the previous curve pattern, and the evidence base for tapering protocols is limited.

Referral, Consultation, and Escalation

Referral or specialist consultation is warranted when the curve shows a pattern that cannot be explained by the current insulin type or dose, when hypoglycemia occurs despite appropriate dose reduction, or when the patient shows clinical signs that do not match the curve findings. Persistent hyperglycemia despite escalating doses, suspected insulin resistance, or concurrent disease that complicates glycaemic control also justify specialist input.

Laboratory involvement is indicated when the curve suggests a confounding condition. This includes measurement of fructosamine to corroborate the curve, assessment of cortisol or thyroid status when resistance is suspected, and evaluation for concurrent infection or inflammation. The American Veterinary Medical Association practice resources provide guidance on professional standards for diagnostic workup and client communication.

Regulatory reporting is rarely required in glucose curve monitoring. It may apply if a glucose meter or test strip is suspected of malfunction in a way that affects patient safety, or if a compounded insulin product is implicated in an adverse event. The World Organization for Animal Health terrestrial animal health standards address disease surveillance and reporting obligations that do not typically extend to individual diabetic patient monitoring.

Frequently Asked Questions

How Should I Proceed When an Owner Cannot Afford Serial Glucose Curves?

Resource limitations are common in practice. When full curves are not feasible, prioritize the single most informative measurement: the expected nadir, based on the insulin type and timing of the peak effect. For most intermediate-acting insulins, this falls 4 to 8 hours after injection. A single nadir sample combined with a fasting or pre-injection glucose can detect the two most dangerous patterns, severe hypoglycemia and persistent hyperglycemia, without the full curve. Urine glucose monitoring offers only a crude directional trend and cannot identify hypoglycemia reliably. Clinical signs, including polydipsia, polyuria, and body weight, remain the cheapest monitoring tool and should always be assessed at re-examination. Document clearly in the record that curve limitations were discussed with the owner.

What Is the Minimum Number of Samples Needed to Adjust Insulin Safely?

No single sample count is universally sufficient, but a minimum of three to four samples is generally required to characterize the nadir and duration of effect. A single pre-injection glucose tells you nothing about the trough or the duration of action. Two samples, one pre-injection and one at the expected peak, can rule out severe hypoglycemia but cannot distinguish a short duration of effect from a flat curve. When only limited sampling is possible, state the interpretive limitation in the medical record and schedule a full curve at the next re-check. The American Society for Veterinary Clinical Pathology quality assurance guidelines emphasize that laboratory data are only as reliable as the sampling protocol that produced them.

How Do I Interpret a Curve When the Dog or Cat Is Also Receiving Glucocorticoids?

Glucocorticoids induce insulin resistance and can flatten the glucose curve, raise the nadir, and shorten the apparent duration of insulin action. If steroid therapy is essential, do not escalate insulin doses aggressively during the first days of treatment. Allow 5 to 7 days for the metabolic effects of the steroid to stabilize before making dose changes based on curve data. If the steroid course is short, consider deferring insulin adjustment until the steroid is withdrawn. When the steroid is long-term, target a slightly higher glucose range than usual to reduce hypoglycemia risk, and warn the owner that insulin requirements may fall when the steroid dose is reduced. Re-check a curve within 7 to 10 days after any steroid dose change.

What Should I Do When In-Hospital Curves Do Not Match the Owner's Home Observations?

Discrepancies between hospital and home glucose values are common and usually reflect stress hyperglycemia, anorexia, or altered activity in the hospital setting. Cats are particularly prone to stress-induced glucose elevation, which can make the hospital curve look worse than the home state. If the owner reports good clinical control, normal body weight, and acceptable thirst and urination, but the hospital curve shows persistent hyperglycemia, trust the clinical picture and request a home curve or continuous glucose monitoring. Conversely, if the owner reports poor control but the hospital curve looks acceptable, question the owner's observation technique and confirm they are using the meter correctly. The MSD Veterinary Manual notes that clinical response should always be weighed alongside laboratory data when adjusting therapy.

How Should I Document Curve Results to Support Future Clinical Decisions?

Record every curve in a standardized format that includes the insulin type, dose, injection time, each glucose value with its timestamp, the nadir, the time to nadir, and the duration of effect. Note the sampling method, in-hospital or home, and any concurrent medications or illnesses. Include the owner's report of clinical signs for the same 24-hour period. This structure allows rapid comparison across visits and prevents repeated misinterpretation of the same pattern. A graphical plot is useful but should always accompany the raw data table. The AVMA practice resources emphasize that complete medical records support continuity of care and defensible clinical decisions.

When Should I Stop Adjusting Insulin Based on Curves and Refer the Case?

Referral is appropriate when the curve pattern is erratic despite consistent dosing, when hypoglycemia occurs repeatedly at low insulin doses, or when the patient requires more than 1.5 U/kg per dose in dogs or more than 0.5 U/kg per dose in cats to achieve any reduction in glucose. Poor response to escalating doses should prompt investigation of concurrent disease, including hyperadrenocorticism, acromegaly, infection, or exocrine pancreatic insufficiency, before referral. Refer early if you suspect insulin resistance from an uncommon cause or if the owner is struggling with technique. A second opinion is also reasonable when you have made three or more dose adjustments without measurable improvement in the curve or clinical signs.

Related Clinical & Scientific Guides

• Peripheral Blood Smear Evaluation: A Step-by-Step Guide
• Reticulocyte Counts in Veterinary Medicine: Clinical Utility and Interpretation
• Cerebrospinal Fluid Analysis in Veterinary Neurology: Collection and Interpretation

References and Further Reading

• Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus.. 2011.
• Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.. 2004.
• Preserved β-cell function in type 1 diabetes by mesenchymal stromal cells.. 2015.
• Marked improvement in carbohydrate and lipid metabolism in diabetic Australian aborigines after temporary reversion to traditional lifestyle.. 1984.
• Stevioside induces antihyperglycaemic, insulinotropic and glucagonostatic effects in vivo: studies in the diabetic Goto-Kakizaki (GK) rats.. 2002.
• A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.. 2011.
• American Society for Veterinary Clinical Pathology Guidelines. American Society for Veterinary Clinical Pathology.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Monitoring Effusion Recurrence and Management in Dogs and Cats
• Monitoring Hepatic Enzyme Trends in Dogs and Cats: Clinical Significance
• Leukogram Patterns in Dogs and Cats: A Diagnostic Guide
• Monitoring Hematologic Recovery After Chemotherapy in Veterinary Patients
• Thrombocytopenia in Dogs and Cats: Diagnostic Approach and Differential Prioritization

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.